Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats
Abstract
Microsatellite instable tumors often respond to immune checkpoint blockade (ICB), however, tumor tissue is unavailable/insufficient in some patients. Two groups are reporting a blood-based assessment of the microsatellite status validated in tumor tissue and by clinical benefit in patient receiving ICB. Both approaches are highly appealing with a few caveats.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2019
- Source ID
- 10.1158/1078-0432.ccr-19-2585
Entities
People
- Jaffer A. Ajani
- Linghua Wang
Organizations
- The University of Texas MD Anderson Cancer Center
- United States Department of Defense
- University of Texas at Austin